Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07224826 in advanced solid tumors
NCT05905341Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of PF-07224826 in triple negative breast cancer (TNBC), ovarian cancer, Liposarcoma and 4 more (7 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities, Adverse Events and 4 more. Planned start Jan 2024; status: withdrawn.
02
Drugs
PF-07224826
03
Conditions
triple negative breast cancer (TNBC)ovarian cancerLiposarcomanon-small cell lung cancer (NSCLC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05905341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905341.